Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback